Greenwich LifeSciences Expands FLAMINGO-01 Trial with City of Hope Sites
Event summary
- Greenwich LifeSciences adds City of Hope as a new clinical site for its Phase III FLAMINGO-01 trial, expanding to Los Angeles, Orange County, Arizona, Atlanta, and Illinois.
- Hope S. Rugo, M.D., a renowned breast cancer expert, joins the Steering Committee from City of Hope while continuing her role at UCSF.
- FLAMINGO-01 trial could grow to 190–200 sites globally, up from the current 160, with potential expansions in the UK and Canada.
- Preliminary data shows a 70–80% reduction in recurrence rates in the non-HLA-A*02 arm, aligning with Phase IIb trial results.
The big picture
The addition of City of Hope, a leading cancer research institution, strengthens Greenwich LifeSciences' Phase III trial footprint and bolsters its credibility in the competitive immunotherapy space. This expansion aligns with broader industry trends toward decentralized clinical trials, aiming to accelerate research while improving patient access to innovative treatments.
What we're watching
- Trial Expansion Dynamics
- The pace at which Greenwich LifeSciences can integrate new sites and maintain data consistency across diverse geographic locations.
- Regulatory Milestones
- Whether the preliminary recurrence rate reductions will hold up under full trial completion and regulatory scrutiny.
- Competitive Positioning
- How GLSI-100's efficacy data compares to existing breast cancer recurrence prevention therapies as the trial progresses.
Related topics